APA (7th ed.) Citation

Dreger, P., & Dietrich, S. (2019). Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: A study by the EBMT Chronic Malignancies and Lymphoma Working Parties. Bone marrow transplantation, 54(1), . https://doi.org/10.1038/s41409-018-0207-4

Chicago Style (17th ed.) Citation

Dreger, Peter, and Sascha Dietrich. "Ibrutinib for Bridging to Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Study by the EBMT Chronic Malignancies and Lymphoma Working Parties." Bone Marrow Transplantation 54, no. 1 (2019). https://doi.org/10.1038/s41409-018-0207-4.

MLA (9th ed.) Citation

Dreger, Peter, and Sascha Dietrich. "Ibrutinib for Bridging to Allogeneic Hematopoietic Cell Transplantation in Patients with Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma: A Study by the EBMT Chronic Malignancies and Lymphoma Working Parties." Bone Marrow Transplantation, vol. 54, no. 1, 2019, https://doi.org/10.1038/s41409-018-0207-4.